Navigation Links
Takeda to Create Global Centers of Excellence
Date:3/30/2009

Reorganization helps Takeda realize globalization vision

OSAKA, Japan, March 30 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced a reorganization of its corporate structure, as part of its 2006-2010 Medium-Term Plan vision to become a global pharmaceutical company with highly integrated global operations. In order to become more responsive to rapid changes in the global operating environment and to maximize the global market potential of new products and the company's global presence, the company is streamlining executive reporting relationships to Yasuchika Hasegawa, President, by creating corporate-level, center of excellence R&D, commercial and administrative functions. Effective April 1, 2009, Shigenori Ohkawa, Ph.D., will become Chief Scientific Officer (CSO), and Alan MacKenzie will become Executive Vice President (EVP) International Operations. Additionally, a Chief Administrative Officer (CAO) role will be established.

"Takeda is making meaningful changes in structure and governance through this reorganization and the creation of the CSO, EVP, International Operations, and CAO roles, which we believe will further strengthen our global operations structure," said Yasuchika Hasegawa, President, Takeda Pharmaceutical Company Limited. "Through this new organizational structure, Takeda looks forward to continuing our history of creating and marketing novel pharmaceutical products that meet the needs of patients globally."

Details of the Reorganization

Effective April 1, 2009, Shigenori Ohkawa, Ph.D., will assume the role of Chief Scientific Officer, responsible for global Research, Development, Chemistry Manufacturing and Controls (CMC), and Intellectual Property (IP). The creation of the CSO role provides the opportunity to further enhance product development effectiveness through the integration of research and development. The CSO will be based in the United States at Takeda's Deerfield, Illinois headquarters and in Osaka, Japan.

Dr. Ohkawa is a member of the Takeda Board of Directors and previously was the General Manager of the Pharmaceutical Research Division. Dr. Ohkawa has been with Takeda for 30 years.

Hiroyuki Odaka, Ph.D., will replace Dr. Ohkawa as General Manager, Pharmaceutical Research Division. Dr. Odaka joined Takeda in 1982 and most recently has been Director of Pharmacology Research Laboratory 1.

Tetsuo Miwa, Ph.D. will become General Manager, CMC Center. Dr. Miwa joined Takeda in 1985 and has held a number of leadership roles in Takeda's research organization, including Director of Discovery Research Center. Most recently, Dr. Miwa belonged to Strategic Product Planning and was in charge of cross-franchise portfolio management and the Millennium acquisition and transition.

Nancy Joseph-Ridge, M.D., will replace Dr. Masaomi Miyamoto as General Manager, Pharmaceutical Development Division. Dr. Joseph-Ridge is currently President of Takeda Global Research & Development Center, Inc., U.S., and will retain this position until her replacement has been announced. She was previously with TAP Pharmaceutical Products Inc.

Yoichi Okumura, will continue in his role as General Manager of Intellectual Property Department. Mr. Okumura joined Takeda in 1984 and has been General Manager of IP Department since 2007.

To ensure further global optimization of the company's pharmaceutical development functions, the global development headquarter functions will be moved to Takeda's Deerfield, Illinois headquarters in the United States, with the transfer anticipated to be complete by July 1. Previously, the Takeda Group's headquarters for development were based in Osaka, Japan, and Takeda managed global development through its regional hubs in Japan, the United States, Europe and a recently established subsidiary in Asia.

Also effective April 1, 2009, Alan MacKenzie will assume the role of EVP, International Operations, responsible for all international (ex-Japan) commercial operations in the United States, Europe, and Asia, as well as global medical affairs and international marketing. The creation of the EVP, International Operations role enhances Takeda's globalization efforts and allows for more streamlined commercial decision making. The EVP, International Operations will be based in the United States at Takeda's Deerfield, Illinois headquarters.

Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceuticals Europe Limited, and Takeda Pharmaceuticals Asia Private Limited will report to EVP, International Operations.

Formerly President and CEO of Takeda Pharmaceuticals North America, Inc. and Executive Vice President of Takeda America Holdings, Inc., Mr. MacKenzie has been with the Takeda family of companies for 24 years. He was a founding executive of Takeda Pharmaceuticals North America, Inc. and past President of TAP Pharmaceutical Products Inc.

Shinji Honda will replace Mr. MacKenzie as CEO, Takeda Pharmaceuticals North America, Inc. Mr. Honda joined Takeda in 1981 and has held a variety of roles in the global organization including Executive Vice President of TAP Pharmaceutical Products Inc. and head of the U.S. Operations Department. Most recently, Mr. Honda was the General Manager of the Overseas Business Planning Department.

Erich Brunn, Ph.D. will continue in his role as CEO of Takeda Pharmaceuticals Europe Limited. Dr. Brunn is responsible for oversight of pan-European sales and marketing. Dr. Brunn was previously President of Takeda Pharma GmbH, a wholly owned subsidiary of Takeda in Germany.

Mr. Stefan Ziegler will continue in his role as CEO of Takeda Pharmaceuticals Asia Private Limited. Mr. Ziegler is responsible for oversight of overall Asian sales and marketing. Mr. Ziegler worked at Novartis from 1990 to 2008.

In conjunction with this reorganization, Takeda has established a new wholly-owned affiliate, Takeda Pharmaceuticals International, Inc. to which the newly established roles of CSO and EVP, International Operations will belong.

Overseas Business Planning Department--which has been a support function for international marketing affiliates as they directly reported to the President, Takeda Pharmaceutical Company Limited--will be dissolved on May 1 following the establishment of the EVP International Operations role.

A CAO role is to be established and will provide comprehensive leadership for the corporate functions of Human Resources, Finance & Accounting, Legal and Corporate Communications. Through a strong understanding of each role, the CAO will promote collaboration between the corporate functions to further strengthen the Company's global strategy.

Additionally, Millennium: The Takeda Oncology Company, will continue to be led by Deborah Dunsire, M.D., reporting directly to the President, Takeda Pharmaceutical Company Limited, and will retain all its current research, global development, global product and marketing strategies, and US commercial responsibilities in the oncology field.


'/>"/>
SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Takeda Receives New Information on Alogliptin (SYR-322) NDA
2. Healthcare Businesswomens Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company
3. Welvista Announces Partnering with Takeda to Provide Medication at No Cost to the Uninsured
4. Review of Takedas Febuxostat New Drug Application Continues Past PDUFA Date
5. FDA Adds Three Months to Review of Takedas New Drug Application for TAK-390MR
6. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
7. Takeda Completes Acquisition of Millennium
8. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
9. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
10. Takeda Announces New U.S. Leadership
11. Takeda submits new drug application for alogliptin (syr-322) in the US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
(Date:6/23/2016)... MEDIA, Pa. , June 23, 2016 ... treatments in an outpatient dialysis facility.  Treatments are usually ... to 6 hours per visit, including travel time, equipment ... on a patient, but especially grueling for patients who ... residents of a skilled nursing and rehabilitation centers for ...
Breaking Medicine Technology: